A phase 2, single arm study of BSI-201 in patients with BRCA-1 or BRCA-2 associated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Trial Profile

A phase 2, single arm study of BSI-201 in patients with BRCA-1 or BRCA-2 associated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Iniparib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Aug 2012 Actual end date changed from Aug 2011 to Jun 2011, as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Actual patient number chnaged from 45 to 12 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top